These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 23778174)
1. Complera for the treatment of HIV. Belavic JM Nurse Pract; 2013 Jul; 38(7):8-10. PubMed ID: 23778174 [No Abstract] [Full Text] [Related]
2. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Lyseng-Williamson KA; Scott LJ Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088 [TBL] [Abstract][Full Text] [Related]
3. Rilpivirine and complera: new first-line treatment options. O'Neal R BETA; 2011; 23(4):14-8. PubMed ID: 22567823 [TBL] [Abstract][Full Text] [Related]
4. Rilpivirine: a step forward in tailored HIV treatment. Schrijvers R; Desimmie BA; Debyser Z Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920 [No Abstract] [Full Text] [Related]
5. First of a kind in HIV treatment. FDA Consum; 2006; 40(6):34. PubMed ID: 17333565 [TBL] [Abstract][Full Text] [Related]
6. European Commission approves Atripla. AIDS Patient Care STDS; 2008 Jan; 22(1):87-8. PubMed ID: 18453042 [No Abstract] [Full Text] [Related]
14. HIV Pathogenesis and Treatment - Third International AIDS Society Conference. Susman E IDrugs; 2005 Oct; 8(10):813-5. PubMed ID: 16254799 [No Abstract] [Full Text] [Related]
15. Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Karim SS; Karim QA Lancet; 2012 Jun; 379(9831):2047-8. PubMed ID: 22608193 [No Abstract] [Full Text] [Related]
16. When is good good enough for HIV-1 prophylaxis? Buchbinder S Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861 [No Abstract] [Full Text] [Related]
17. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. Liu A; Cohen S; Follansbee S; Cohan D; Weber S; Sachdev D; Buchbinder S PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035 [TBL] [Abstract][Full Text] [Related]
18. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Stürmer M; Staszewski S; Doerr HW Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153 [TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle toxicity associated with emtricitabine/rilpivirine/tenofovir fixed-dose combination: a case report. Nguyen LB; Harent S; Peytavin G; Visseaux B; Bastard JP; Dubourg O; Lariven S; Patrick Yeni ; Yazdanpanah Y; Lescure FX AIDS; 2014 Aug; 28(13):1995-7. PubMed ID: 25259710 [No Abstract] [Full Text] [Related]
20. Drug interactions. Super pills-the treatments of the future? TreatmentUpdate; 2006; 18(3):2-3. PubMed ID: 17209236 [No Abstract] [Full Text] [Related] [Next] [New Search]